NEW
FIND THE RIGHT FIT. FAST.^*

51% of patients respond to treatment with 84% survival rate at 1 year for responders with EBVALLO, the first and only on-demand T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD in Europe¹

EBVALLO^® is indicated as monotherapy for the treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory EBV+ PTLD who have received at least one prior therapy. For SOT patients, prior therapy includes chemotherapy unless chemotherapy is considered inappropriate²

EBV+, Epstein-Barr virus positive; PTLD, post-transplant lymphoproliferative disease; SOT, solid organ transplantation.

*Data on file - Clinical overview EBV+, Epstein-Barr virus positive; ORR, objective response rate; PTLD, post-transplant lymphoproliferative disease; SOT, solid organ transplantation.

EBVALLO is the first and only on-demand allogeneic T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD³

EBVALLO demonstrates clinically meaningful outcomes in patients with relapsed or refractory EBV+ PTLD with limited treatment options and poor survival^1,5,6

Median OS post rituximab +/- chemotherapy failure

0.7 months post HCT⁵
4.1 months post SOT⁶

About EBV+ PTLD

Is the first and only on-demand allogeneic T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLDrituximab
+/- chemotherapy failure¹

About EBVALLO

51% ORR
84% 1-yr OS in responders
In the ALLELE Study¹

Efficacy

Well tolerated and no reports of immune-related reactions¹

Safety

EBV+, Epstein-Barr virus positive; PTLD, post-transplant lymphoproliferative disease; OS, overall survival; HCT, haematopoietic cell transplantation; SOT, solid organ transplantation; ORR, objective response rate

References

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

1. Mahadeo, K.M. et al. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr viruspositive post-transplant lymphoproliferative disease after failure of Rituximab or rituximab and chemotherapy (allele): A phase 3, Multicentre,
open-label trial. The Lancet Oncology, January 2024.
2. EBVALLO Summary of Product Characteristics.
3. Dierickx D, et al. Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018;378:549–562.
4. Nijland ML, et al. Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct. 2016;2(1):e48.
5. Sanz J, et al. Abstract 1454. Presented at: ASH Annual Meeting and Exposition; December 11–14, 2021; Atlanta. Clinical Outcomes of Patients with Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab:A Multinational, Retrospective Chart Review Study. Blood. 2021;138(Suppl 1):1454.
6. Dharnidharka V, et al. Abstract 2528. Presented at: ASH Annual Meeting and Exposition; December 11–14, 2021; Atlanta. Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study. Blood. 2021;138(Suppl 1):2528.
7. EBVALLO EPAR.

This is an international website for EBVALLO®. IMPORTANT: This material was developped in compliance with EFPIA code and EBVALLO EU SmPC. Registration conditions and prescribing information may vary per country. Therefore, before prescribing any product, Health Care Providers must refer to their country's prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

Last update: 04/2024

NEW FIND THE RIGHT FIT. FAST.*

EBVALLO is the first and only on-demand allogeneic T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD3​

NEW
FIND THE RIGHT FIT. FAST.^*

EBVALLO is the first and only on-demand allogeneic T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD³